NEULAND LABS share price has plunged 7% and is presently trading at Rs 11,211.2.
Meanwhile, the BSE HEALTHCARE index is at 43,134.9 (down 1.0%).
Among the top losers in the BSE HEALTHCARE index today are GSK Pharma (down 4.2%) and SUVEN PHARMACEUTICALS (down 4.1%).
ASTRAZENECA PHARMA (up 3.7%) and Natco Pharma (up 2.2%) are among the top gainers today.
Over the last one year, NEULAND LABS has moved up from Rs 3,741.2 to Rs 11,211.2, registering a gain of Rs 7,470.0 (up 199.7%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,134.9, registering a gain of 51.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 149.8%), SUVEN PHARMACEUTICALS (up 100.4%) and Glenmark Pharma (up 97.4%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 81,178.8 (down 0.6%).
The top losers among the BSE Sensex today are NTPC (down 4.1%) and MUNDRA PORT & SEZ (down 3.8%). The most traded stocks in the BSE Sensex are Tata Steel and Axis Bank.
In the meantime, NSE Nifty is at 24,793.9 (down 0.9%). NTPC and MUNDRA PORT & SEZ are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 81,178.8, registering a gain of 15,666.7 points (up 23.9%).
NEULAND LABS net profit grew 58.2% YoY to Rs 979 million for the quarter ended June 2024, compared to a profit of Rs 619 million a year ago. Net sales rose 21.1% to Rs 4,396 million during the period as against Rs 3,630 million in April-June 2023.
For the year ended March 2024, NEULAND LABS reported 83.5% increase in net profit to Rs 3,001 million compared to net profit of Rs 1,635 million during FY23. Revenue of the company grew 30.8% to Rs 15,586 million during FY24.
The current Price to earnings ratio of NEULAND LABS, based on rolling 12 month earnings, stands at 42.8.
Equitymaster requests your view! Post a comment on "NEULAND LABS Plunges 7%; BSE HEALTHCARE Index Down 1.0%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!